Navigation path

Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information

Recombinant human rod-derived cone viability factor

EU orphan designation number: EU/3/07/500
Active ingredient: Recombinant human rod-derived cone viability factor
Indication: Treatment of retinitis pigmentosa
Sponsor: Fovea Pharmaceuticals SA
Institut de la Vision, 17 rue Moreau, F-75012 Paris, France

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
03/12/2007 Orphan designation EMEA/OD/075/07 (2007)6020 of 29/11/2007
25/02/2009 Change of name and/or address of sponsor
30/07/2014 Removal of orphan designation from Community Register